Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIS51ON: High-dose Eteplirsen in DMD
NCT03992430Phase 3Active, not recruiting
- Sponsor
- Sarepta Therapeutics
- Start
- Jul 2020
- Primary completion
- Oct 2026
- Countries
- 26
01
Overview
A Phase 3 trial of eteplirsen in Duchenne muscular dystrophy (DMD), sponsored by Sarepta Therapeutics. Started Jul 2020; status: active, not recruiting.
02
Drugs
eteplirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03992430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03992430.